Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page
- Check2 days agoChange DetectedThe study record now includes a Results Posted entry and updates to several primary and secondary outcomes (e.g., disease control rate at 12 weeks, PSA dynamics, radiographic progression, and treatment-related adverse events) along with related documents. Several older PSA-related outcomes were removed.SummaryDifference3%

- Check10 days agoChange DetectedAdds related-topic references for Prostate cancer and MedlinePlus Genetics to the page, improving quick access to background resources related to the study.SummaryDifference0.2%

- Check17 days agoChange DetectedThe Study Record Dates section now shows Revision: v3.5.3 replacing v3.5.2, indicating an updated page revision. This reflects an administrative update to the record rather than changes to study information.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the page footer. No other visible changes to trial details or content.SummaryDifference0.1%

- Check46 days agoChange DetectedA 'Results Submitted' section was added and the 'No Results Posted' note was removed.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page adds the Prostate cancer tag and related topics such as MedlinePlus Genetics. The site revision is updated from v3.4.3 to v3.5.0.SummaryDifference0.2%

Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.